MAO/ASSESSMENT OF HUMORAL IMMUNE RESPONSES (G)

HIV临床前疫苗开发主协议计划 启动以使NIAID能够提供资源，以加速 开发有前景的疫苗方法。在这个项目下， 已经启动了疫苗研究，以评估候选疫苗， 在非人类灵长类动物中的原型艾滋病疫苗。这些研究旨在 以获得更多关于功效和最佳呈现的信息， 在人体I期临床试验中的候选HIV疫苗，或 以及相同的原型SIV疫苗 就像这些艾滋病疫苗一样。其他疫苗研究将评估原型 提供新型呈递系统的HIV或SIV疫苗可能能够 引发广泛的交叉反应性免疫反应，或者已经显示 有希望的初步结果。NIAID已启动合作 与同意提供艾滋病毒和SIV的研究人员达成协议， 用于非人灵长类动物免疫的疫苗。在所有的疫苗中 研究中，非人灵长类动物将在免疫后受到挑战， 确定是否可以获得免受感染或疾病的保护。 主协议计划G类承包商，包括 上述承包商将评估抗体的能力 在疫苗免疫期间在非人灵长类动物中产生， 中和SIV和/或HIV的感染性，使用体外测定， 评估这项活动。

The HIV Preclinical Vaccine Development Master Agreement Program was initiated to enable the NIAID to provide resources to accelerate the development of promising vaccine approaches. Under this program, a senses of vaccine studies have been initiated to evaluate candidate and prototype AIDS vaccines in nonhuman primates. These studies are designed to obtain more information about the efficacy and optimum presentation of candidate HIV vaccines that are in human Phase I clinical trials or proposed for such trials as well as prototype SIV vaccines of the same type as these HIV vaccines. Other vaccine studies will evaluate prototype HIV or SIV vaccines that offer novel presentation systems may be capable of eliciting broadly cross-reactive immune responses, or have shown promising preliminary results. NIAID has initiated collaborative arrangements with researchers who have agreed to provide HIV and SIV vaccines for immunization of nonhuman primates. In all of the vaccine studies, the nonhuman primates will be challenged after immunization to determine if protection from infection or from disease can be obtained. The contractors in Category G of the Master Agreement Program, including the contractor listed above, will evaluate the ability of antibodies produced in the nonhuman primates during vaccine immunization to neutralize the infectivity of SIV and/or HIV, using in vitro assays to assess this activity.